还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

                               
登录/注册后可看大图

请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

% R3 ~5 B2 C) o4 X: y! x可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  

, ?' a8 h# ?- H. a
Sub-category:
Molecular Targets


Category:
) r" U* r' v* ETumor Biology

( a; `: P  z  ^, ]
* t/ z, b( U, f1 X. `# qMeeting:
% S. O' k  j4 z5 J# K  T2011 ASCO Annual Meeting
5 G0 O) E8 t2 j  d6 m; y+ w2 y

' O8 I2 ~( J) X: Q+ kSession Type and Session Title:
Poster Discussion Session, Tumor Biology


Abstract No:
; [' p* K5 V* k; r$ v. [10517
  t1 t8 k* H6 }$ S- u% f5 N
  y8 {  w- K# e
5 v9 T/ x1 [0 `" l2 CCitation:
8 G2 l8 b/ F1 I0 WJ Clin Oncol 29: 2011 (suppl; abstr 10517)


Author(s):
) z/ y1 R3 t6 Z" N0 e0 U! Z1 }2 x, nJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
- u4 s; [* y- c  D7 x1 W


8 v, S0 P. W" M7 x9 Y9 KAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
( a0 o0 ?2 G4 }  F8 Z& Y- I' @
. x0 x* y0 B; c5 x, O8 a& e  hAbstract Disclosures

Abstract:
( c4 \& Z7 @" I

Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.


! k3 i3 Y) x0 G+ ~9 n9 O

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

                               
登录/注册后可看大图

) o6 i  ?1 r- e# S7 w没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

, e0 v! d, K# U化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

                               
登录/注册后可看大图

+ V+ E/ `2 e6 L, P; u易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
9 I" R/ t) {* Y$ S+ KALK一个指标医院要900多 ...

平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？

" B5 d- A" \* h现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊